Supernus Pharmaceuticals, Inc. (SUPN) Downgraded by Stifel Nicolaus
Stifel Nicolaus cut shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from a buy rating to a hold rating in a research report report published on Tuesday, Marketbeat.com reports. The brokerage currently has $47.00 price objective on the specialty pharmaceutical company’s stock. The analysts noted that the move was a valuation call.
SUPN has been the subject of several other reports. BidaskClub downgraded shares of Supernus Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, August 2nd. Jefferies Group LLC restated a buy rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Janney Montgomery Scott began coverage on shares of Supernus Pharmaceuticals in a research report on Friday, July 14th. They set a neutral rating and a $47.00 price objective for the company. Cowen and Company restated a positive rating and set a $50.00 price objective (up from $40.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a neutral rating on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $48.29.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded down 0.38% during trading on Tuesday, hitting $39.25. The stock had a trading volume of 173,691 shares. Supernus Pharmaceuticals has a 12-month low of $17.25 and a 12-month high of $50.05. The stock’s 50-day moving average is $44.56 and its 200-day moving average is $37.95. The stock has a market capitalization of $1.99 billion, a P/E ratio of 19.80 and a beta of 1.30.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. Analysts predict that Supernus Pharmaceuticals will post $1.04 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Downgraded by Stifel Nicolaus” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/22/supernus-pharmaceuticals-inc-supn-downgraded-by-stifel-nicolaus.html.
In other news, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 3,735 shares of the company’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total transaction of $167,701.50. Following the transaction, the vice president now owns 21,209 shares of the company’s stock, valued at $952,284.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 157,444 shares of company stock valued at $7,390,810. Company insiders own 6.70% of the company’s stock.
Large investors have recently made changes to their positions in the company. Neumeier Poma Investment Counsel LLC increased its holdings in shares of Supernus Pharmaceuticals by 1.6% during the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after buying an additional 14,430 shares in the last quarter. Sheets Smith Wealth Management acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth $378,000. Royce & Associates LP increased its holdings in shares of Supernus Pharmaceuticals by 22.3% during the second quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock worth $6,853,000 after buying an additional 29,000 shares in the last quarter. Turner Investments LLC acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth $219,000. Finally, Bank of America Corp DE increased its holdings in shares of Supernus Pharmaceuticals by 10.7% during the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock worth $11,361,000 after buying an additional 35,069 shares in the last quarter. Institutional investors own 95.38% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.